-
Mashup Score: 0
Investigators conducted a multicenter, double-blind, randomized, placebo-controlled trial to evaluate the impact of cannabinoids on peripheral neuropathic pain.
Source: Clinical Pain AdvisorCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 1
This page is a resource for the research community to assist with identifying National Institutes of Health (NIH) Institutes’ research interests, relevant funding opportunities, and appropriate staff contacts for guidance on particular funding opportunity announcements (FOAs).
Source: NCCIHCategories: Healthcare Professionals, Latest HeadlinesTweet-
Find out about @NIH-supported research on #cannabis, cannabinoids, and related compounds, including funding opportunities for #cannabinoid research, from this new @NIH_NCCIH website. https://t.co/mH6sibvbLm
-
-
Mashup Score: 1
Investigators sought to determine the impact of placebo on pain response in studies evaluating cannabinoids and cannabis-based products.
Source: Clinical Pain AdvisorCategories: Healthcare Professionals, Latest HeadlinesTweet-
ICYMI: #Placebo Has Significant #Pain Reduction Effect in #Cannabinoid Clinical Trials https://t.co/GVp9xEGZXP #Cannabis #cannabidiol #CBD https://t.co/92xto0wxgj Results are not surprising, given media attention, desperation, other factors. Didn't work for me! #neuropathicpain https://t.co/6wqVQWh91g
-
-
Mashup Score: 0
NIH Funding Opportunities and Notices in the NIH Guide for Grants and Contracts: Cannabis and Cannabinoid Use in Adult Cancer Patients During Treatment: Assessing Benefits and Harms (U01 Clinical Trial Not Allowed) RFA-CA-22-052. NCI
Source: grants.nih.govCategories: Healthcare Professionals, Latest HeadlinesTweet-
February 17, 2023, is the deadline to apply for the #FundingOpp from @theNCI, @NIDAnews, and @NIH_NCCIH for studies on #cannabis and #cannabinoid use in adult cancer patients during treatment. https://t.co/kyN4W8Mzf3
-
-
Mashup Score: 0
NIH Funding Opportunities and Notices in the NIH Guide for Grants and Contracts: Cannabis and Cannabinoid Use in Adult Cancer Patients During Treatment: Assessing Benefits and Harms (U01 Clinical Trial Not Allowed) RFA-CA-22-052. NCI
Source: grants.nih.govCategories: Healthcare Professionals, Latest HeadlinesTweet-
A new #FundingOpp from @theNCI, @NIDAnews, and @NIH_NCCIH will support studies to assess the benefits and harms of #cannabis or #cannabinoid use by adult patients during cancer treatment. https://t.co/kyN4W8uYnv
-
-
Mashup Score: 1
The purpose of this RFI is to solicit information from the scientific research community about its interest in and barriers to research on the health effects of cannabis and its constituents.
Source: NCCIHCategories: Healthcare Professionals, Latest HeadlinesTweet-
The responses to this RFI will help us to address the challenges and needs for #cannabis and #cannabinoid research and identify areas of interest within this field. https://t.co/TV67r1nuE2 https://t.co/2wgbRA9Phq
-
-
Mashup Score: 0
52 cases were ultimately identified, and four patients died
Source: www.medpagetoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Unexplained bleeding in dozens of patients with a history of synthetic #cannabinoid use was linked to poisoning with #brodifacoum, an #anticoagulant often used in rat poison, reported Nikki Coble, MPH, of @HealthyFla: https://t.co/wB6ZXZT6Cj @Jen_Henderson1
-
-
Mashup Score: 0Positive results shown in ongoing phase 2 trial of cannabinoid intoxication treatment - 2 year(s) ago
A biopharmaceutical company has announced positive interim data from the first two cohorts in an ongoing phase 2 clinical trial of its treatment for acute cannabinoid intoxication. According to a release from Anebulo Pharmaceuticals, ANEB-001 is an orally bioavailable, rapidly absorbed, small molecule cannabinoid receptor antagonist that aims to address the unmet medical need for a specific
Source: www.healio.comCategories: General Medicine News, Latest HeadlinesTweet-
Biopharma company @AnebuloP has announced positive interim data from the first two cohorts in an ongoing phase 2 clinical trial of its treatment for acute #cannabinoid intoxication. https://t.co/OxsOSqYwVN
-
-
Mashup Score: 0
High-dose haloperidol and aprepitant were both associated with emergency department discharge.
Source: Contemporary PediatricsCategories: Latest Headlines, PediatricsTweet-
As more states legalize recreational #marijuana, data have shown an increase in cannabis use among teenagers, some of which may develop #cannabinoid hyperemesis syndrome. https://t.co/ZsRzpGnvTJ https://t.co/fbRp0MHS2O
-
-
Mashup Score: 2Activation of CD4+ T Cell–Derived Cannabinoid Receptor 2 Signaling Exacerbates Sepsis via Inhibiting IL-10 - 2 year(s) ago
The cannabinoid receptor 2 (CB2) is a receptor mainly expressed in immune cells and believed to be immunosuppressive in infective or inflammatory models. However, its role in sepsis has not been fully elucidated. In this study, we delineate the function and mechanism of CB2 in the cecal ligation and
Source: The Journal of ImmunologyCategories: Allergy-Immunology, Latest HeadlinesTweet-
Activation of the #CD4Tcell-derived #cannabinoid receptor CN2 increases susceptibility to #sepsis through #IL10 inhibition | from Guoliang Zhang at The Third People's Hospital of Shenzhen & colleagues @Sydney_Uni | #ReadTheJI #immunology https://t.co/EJtnlXGa3w https://t.co/3418pHQSYt
-
Study Shows No Benefit With #CBD, #THC for Peripheral #NeuropathicPain https://t.co/rwdBYETQCG #RCT #clinicaltrial #cannabinoid Oral capsules of .. (THC), #cannabidiol (CBD) and their combination in peripheral neuropathic pain treatment https://t.co/epZn3RMgAG